11 January 2022 in American Journal of Clinical Dermatology
6 March 2023 in Endocrine Practice
7 October 2022 in Adolescent Health, Medicine and Therapeutics
Transgender adolescents seek gender-affirming medical care to address gender identity and incongruence. Improved understanding of the dermatologic impact of gender-affirming medical care such as pubertal suppression, hormone therapy, and surgeries can enhance patient outcome. Pubertal suppression treats dysphoria associated with development of secondary sex characteristics, including androgen-driven acne. Gender-affirming hormone therapy influences acne and hair development in transgender adolescents. Dermatologists can help manage skin effects associated with chest binding and gender-affirming hormone therapy and surgery. Provision of patient-centered gender-affirming care in dermatologic and multidisciplinary settings is essential to improve skin and overall outcomes of gender-affirming therapy.
1 November 2025 in Archives of Dermatological Research
This study aimed to identify barriers and facilitators influencing transgender individuals’ participation in teledermatology-based acne research and their perceptions of artificial intelligence use in acne research. This was a qualitative study conducted between 2021 and 2023. Transgender and gender diverse individuals who received gender-affirming hormone therapy and had acne were recruited from a public safety-net hospital and from academic endocrinology and dermatology clinics. Semi-structured interviews exploring factors influencing teledermatology-based acne research participation were analyzed using thematic analysis. Among 32 participants, 17 (53%) identified as transgender men, 11 (34%) as transgender women, and 4 (13%) as non-binary or other gender identities. Mild or lower acne severity was reported by 21 (66%) participants, while 11 (34%) reported moderate-to-severe acne. Access to equipment and comfort in photographing sensitive areas determined capability of participation in hypothetical teledermatology research. Accessibility, flexibility, and reduced transportation cost of remote research, and in-clinic recruitment from established clinicians presented opportunities for participation. Motivating factors included trust in research team members, privacy concerns, and improving acne treatment for transgender individuals. Perspectives on artificial intelligence were mixed and included concerns regarding security and potential for bias. Teledermatology offers opportunity to improve recruitment and retention of transgender individuals in acne research. Incorporating perspectives of transgender individuals can inform the design of future teledermatology research on acne in the context of gender-affirming hormone therapy.
4 November 2026 in Pediatric Dermatology
Acne vulgaris commonly presents in early adolescence with the onset of adrenarche. Treatments for acne in this age group typically mirror those in older adolescents. However, while combined oral contraceptives are an effective hormonal treatment for acne vulgaris in young women, the safety of using a systemic hormonal therapy in younger patients for the management of acne has not been established. Concerns include effects on pubertal development and weight, bone health, cancer risks, and psychiatric effects. This Pediatric Dermatology Research Alliance (PeDRA) consensus project convened a multidisciplinary work group to address these issues and, utilizing a modified Delphi process, to establish best practices regarding the use of combined oral contraceptives in patients under 16 years of age based on available evidence and expert opinion.